Medidata unveils AI imaging solution
Analysis based on 6 articles · First reported May 28, 2026 · Last updated May 28, 2026
The unveiling of Dassault Systèmes — Medidata Solutions's AI-powered imaging solution is expected to positively impact the biotechnology and healthcare sectors by accelerating clinical trials and improving treatment efficacy. This innovation could lead to increased investor confidence in Dassault Systèmes — Medidata Solutions and its parent company, Dassault Systèmes, potentially boosting their stock performance.
Dassault Systèmes — Medidata Solutions, a Dassault Systèmes brand, unveiled its enhanced AI-powered imaging solution, Dassault Systèmes — Medidata Solutions Imaging, at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting. This solution integrates AI with clinical study team feedback to improve accuracy and speed in clinical trials, particularly in oncology. Key features include 32% faster Protected Health Information redaction, over 97% accuracy in anatomy verification, and quality control results in minutes. Wayne Walker, Senior Vice President, Data Experience at Dassault Systèmes — Medidata Solutions, highlighted the critical role of imaging in oncology trials and the transformative power of AI in accelerating clinical breakthroughs. Dassault Systèmes — Medidata Solutions plans further advancements, including enhanced tumor detection and one-click image transfers, leveraging its network of over 1,000 U.S. hospitals.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard